Core Insights - Lexeo Therapeutics announced positive interim data for LX2006 in treating Friedreich ataxia (FA) cardiomyopathy, with significant improvements in frataxin expression and left ventricular mass index (LVMI) [1][3] - The company plans to initiate a registrational study for LX2006 by early 2026 and will begin enrollment in a natural history study, CLARITY-FA, in Q2 2025 [1][2] - Lexeo is also advancing LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, with interim data expected in the second half of 2025 [1][3] Business and Program Updates - LX2006 for FA Cardiomyopathy: Positive interim data from both SUNRISE-FA and Weill Cornell Medicine trials showed a 25% mean reduction in LVMI and a 115% increase in cardiac frataxin expression in the high-dose cohort [3] - Safety Profile: LX2006 has been well tolerated with no new serious adverse events reported [3] - Regulatory Plans: Final alignment with the FDA on the pivotal study protocol is expected in 2025, with co-primary endpoints established [3] - Next Steps: Enrollment for the CLARITY-FA study will begin in Q2 2025, with a registrational study anticipated to start by early 2026 [3] Financial Overview - Capital Redeployment: Lexeo redeployed $20 million towards clinical-stage programs, focusing on LX2006 and LX2020, while reducing workforce by approximately 15% [4] - Cash Position: As of March 31, 2025, Lexeo reported cash, cash equivalents, and investments totaling $106.9 million, expected to fund operations into 2027 [8][10] - Financial Results: For Q1 2025, Lexeo reported a net loss of $32.7 million, or $0.99 per share, compared to a net loss of $21.7 million, or $0.77 per share, in Q1 2024 [8][9]
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights